+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

2019 Tardive Dyskinesia Clinical Trials Guide- Companies, Drugs, Phases, Subjects, Current Status and Outlook to 2025

  • ID: 4767976
  • Report
  • 57 pages
  • VPA Research
1 of 3

FEATURED COMPANIES

  • Celerion Inc
  • E. Merck KG
  • Medicure Inc
  • Synchroneuron Inc
  • UCB SA
  • MORE
The global clinical trial report- “2019 Tardive Dyskinesia Clinical Trials Study” provides complete list of trials completed, ongoing and planned for Tardive Dyskinesia. It presents in-depth analysis of Tardive Dyskinesia clinical trials across markets and companies. The research work is for providing complete understanding into trends in Tardive Dyskinesia.

The report covers a key snapshot of trial trends, enrollment trends, success trends, locations and other trends.

It also segments the Tardive Dyskinesia clinical trials by:
  • Current Trial Status
  • Type of the trial
  • Sponsor Type
  • Enrollment Trends
  • Region
  • Countries
  • Trial Phase
The report also identifies the potential drug candidates under development for treatment of Tardive Dyskinesia

The research work is prepared through extensive and continuous research on Tardive Dyskinesia trials from over 1500 sources including company websites, conferences and presentations, scientific journals, country wise and global clinical trial registries, news, health and science departments among others.

Report Scope and Coverage:
  • All major trials from 2010 to 2019 and planned trials are included in the report scope.
  • Drug candidates currently being researched for administering Tardive Dyskinesia patients are identified
  • The report includes panorama of Tardive Dyskinesia clinical trials across the globe
  • Trial Phase, Current Status, Sponsor Type, Location, trial type and Enrollment details are provided
  • Companies and universities focusing on Tardive Dyskinesia clinical trials are analyzed along with their trial participation (trial title, trial phase and current status)
  • Average Enrollment number, insights into enrollment trends, company wise enrollment are included
  • Both interventional and observational studies are analyzed
  • News and latest developments for the past one year are presented in the report
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Celerion Inc
  • E. Merck KG
  • Medicure Inc
  • Synchroneuron Inc
  • UCB SA
  • MORE
1.1 List of Figures
1.2 List of Tables

2. Executive Summary
2.1 Tardive Dyskinesia Clinical Trials Overview, 2019
2.2 Premium Insights into Clinical Trials
2.2.1 Tardive Dyskinesia Clinical Trials by Region
2.2.2 Average Enrollment of Tardive Dyskinesia Clinical Trials
2.2.3 Companies participating in Trials
2.2.4 Drugs under Study for Tardive Dyskinesia Treatment, 2019

3. Region wise Tardive Dyskinesia Clinical Trials
3.1 Asia Pacific Tardive Dyskinesia Clinical Trials by Country
3.2 Europe Tardive Dyskinesia Clinical Trials by Country
3.3 North America Tardive Dyskinesia Clinical Trials by Country
3.4 Middle East and Africa Tardive Dyskinesia Clinical Trials by Country
3.5 South and Central America Tardive Dyskinesia Clinical Trials by Country

4. Tardive Dyskinesia Clinical Trial Trends
4.1 Start Year wise Tardive Dyskinesia Clinical Trials
4.2 Phase wise Tardive Dyskinesia Clinical Trials
4.3 Trial Status wise Tardive Dyskinesia Clinical Trials
4.4 Trial Type wise Tardive Dyskinesia Clinical Trials

5. Tardive Dyskinesia Average Enrollment Trends
5.1 Average Enrollment in Tardive Dyskinesia Trials by Year
5.2 Average Enrollment in Tardive Dyskinesia Trials by Phase
5.3 Average Enrollment in Tardive Dyskinesia Trials by Status
5.4 Average Enrollment in Tardive Dyskinesia Trials by Type of Trial

6. Companies Participating in Tardive Dyskinesia Clinical Trials
6.1 Tardive Dyskinesia Trials by Sponsor Type
6.2 Tardive Dyskinesia Average Enrollment by Sponsor Type
6.3 Subjects Recruited by Leading Sponsors

7. Trial Snapshots- Phase, Type, Title, Location, Start Year, Completion Year, Recruitment Status, Enrollment, Participating Countries, Trial Locations, Company, Drugs and Other Details
7.1 Tardive Dyskinesia Trials- Phase 1
7.2 Tardive Dyskinesia Trials- Phase 2
7.3 Tardive Dyskinesia Trials- Phase 3
7.4 Tardive Dyskinesia Trials- Phase 4

8. Appendix
8.1 Report Guidance
8.2 Research Methodology
8.3 Abbreviations
8.4 Definitions
8.5 Sources
8.6 Publisher Expertise

List of Figures
Figure 1: Tardive Dyskinesia Clinical Trials by Region, 2019
Figure 2: Country wise Clinical Trials, 2019
Figure 3: Country wise Average Enrolment, 2019
Figure 4: Asia Pacific - Country wise Tardive Dyskinesia Clinical Trials and Enrolment
Figure 5: Europe - Country wise Tardive Dyskinesia Clinical Trials and Enrolment
Figure 6: Middle East Africa - Country wise Tardive Dyskinesia Clinical Trials and Enrolment
Figure 7: North America - Country wise Tardive Dyskinesia Clinical Trials and Enrolment
Figure 8: South and Central America - Country wise Tardive Dyskinesia Clinical Trials and Enrolment
Figure 9: Tardive Dyskinesia Clinical Trials by Phase
Figure 10: Tardive Dyskinesia Clinical Trials by Trial Status
Figure 11: Tardive Dyskinesia Clinical Trials by Type
Figure 12: Tardive Dyskinesia Clinical Trials by Sponsor Type
Figure 13: Tardive Dyskinesia Clinical Trials by Leading Sponsors
Figure 14: Tardive Dyskinesia Average Enrollment by Phase
Figure 15: Tardive Dyskinesia Average Enrollment by Trial Status
Figure 16: Tardive Dyskinesia Average Enrollment by Type
Figure 17: Tardive Dyskinesia- Average Enrolment by Type of Sponsors
Figure 18: Tardive Dyskinesia- Enrolment by Leading Sponsors
Figure 19: Research Methodology

List of Tables
Table 1: Tardive Dyskinesia Clinical Trials Snapshot- 2019
Table 2: Trials by Region, 2019
Table 3: Country wise Clinical Trials and Average Enrolment by Country, 2019
Table 4: Asia Pacific - Country wise Tardive Dyskinesia Clinical Trials and Enrolment
Table 5: Europe - Country wise Tardive Dyskinesia Clinical Trials and Enrolment
Table 6: Middle East Africa - Country wise Tardive Dyskinesia Clinical Trials and Enrolment
Table 7: North America - Country wise Tardive Dyskinesia Clinical Trials and Enrolment
Table 8: South and Central America - Country wise Tardive Dyskinesia Clinical Trials and Enrolment
Table 9: Clinical Trials by Phase
Table 10: Clinical Trials by Trial Status
Table 11: Clinical Trials by Type
Table 12: Clinical Trials by Sponsor Type
Table 13: Clinical Trials by Leading Sponsors
Table 14: Tardive Dyskinesia Average Enrollment by Phase
Table 15: Tardive Dyskinesia Average Enrollment by Trial Status
Table 16: Tardive Dyskinesia Average Enrollment by Type
Table 17: Tardive Dyskinesia- Average Enrolment by Type of Sponsors
Table 18: Tardive Dyskinesia- Enrolment by Leading Sponsors
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • Adamas Pharmaceuticals Inc
  • Aop Orphan Pharmaceuticals AG
  • Celerion Inc
  • E. Merck KG
  • Medicure Inc
  • Mitsubishi Chemical Holdings Corp
  • Neurocrine Biosciences Inc
  • Synchroneuron Inc
  • Teva Pharmaceutical Industries Ltd
  • UCB SA
Note: Product cover images may vary from those shown
Adroll
adroll